NO20033456D0 - Modifiserte og stabiliserte GDF-propeptider og anvendelse derav - Google Patents

Modifiserte og stabiliserte GDF-propeptider og anvendelse derav

Info

Publication number
NO20033456D0
NO20033456D0 NO20033456A NO20033456A NO20033456D0 NO 20033456 D0 NO20033456 D0 NO 20033456D0 NO 20033456 A NO20033456 A NO 20033456A NO 20033456 A NO20033456 A NO 20033456A NO 20033456 D0 NO20033456 D0 NO 20033456D0
Authority
NO
Norway
Prior art keywords
modified
gdf propeptides
stabilized gdf
stabilized
propeptides
Prior art date
Application number
NO20033456A
Other languages
English (en)
Other versions
NO333427B1 (no
NO20033456L (no
Inventor
Neil M Wolfman
Soo Peang Khor
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20033456D0 publication Critical patent/NO20033456D0/no
Publication of NO20033456L publication Critical patent/NO20033456L/no
Publication of NO333427B1 publication Critical patent/NO333427B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20033456A 2001-02-08 2003-08-04 Modifiserte GDF-8-propeptider, fremgangsmate for fremstilling og anvendelse derav, nukleinsyremolekyl kodende for modifisert GDF-8-propeptid, samt farmasoytisk preparat NO333427B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26750901P 2001-02-08 2001-02-08
PCT/US2002/003467 WO2002068650A2 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof

Publications (3)

Publication Number Publication Date
NO20033456D0 true NO20033456D0 (no) 2003-08-04
NO20033456L NO20033456L (no) 2003-10-06
NO333427B1 NO333427B1 (no) 2013-06-03

Family

ID=23019083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033456A NO333427B1 (no) 2001-02-08 2003-08-04 Modifiserte GDF-8-propeptider, fremgangsmate for fremstilling og anvendelse derav, nukleinsyremolekyl kodende for modifisert GDF-8-propeptid, samt farmasoytisk preparat

Country Status (23)

Country Link
US (6) US7202210B2 (no)
EP (1) EP1397492B1 (no)
JP (3) JP4280071B2 (no)
AR (1) AR032567A1 (no)
AT (1) ATE357519T1 (no)
AU (1) AU2002243852B2 (no)
BR (1) BR0207110A (no)
CA (2) CA2437218A1 (no)
CL (1) CL2009000648A1 (no)
CY (1) CY1106629T1 (no)
DE (1) DE60219006T2 (no)
DK (1) DK1397492T3 (no)
ES (1) ES2284828T3 (no)
HK (1) HK1062457A1 (no)
MX (1) MXPA03007063A (no)
NO (1) NO333427B1 (no)
NZ (2) NZ527286A (no)
PL (2) PL212078B1 (no)
PT (1) PT1397492E (no)
SG (2) SG165982A1 (no)
TW (2) TWI329129B (no)
WO (1) WO2002068650A2 (no)
ZA (2) ZA200508954B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
MXPA04008149A (es) * 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
KR20060026860A (ko) * 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
MX2007000976A (es) * 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
US20060240488A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
EP3231442B1 (en) * 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
CA2660523C (en) * 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101803620B1 (ko) * 2006-12-18 2017-11-30 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉ 길항물질과 적혈구 수준을 증가시키기 위한 이의 용도
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
JP5237970B2 (ja) * 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW202021980A (zh) * 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2120999B1 (en) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
EP2167135A2 (en) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CN101815535B (zh) * 2007-07-12 2013-04-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
ES2617957T3 (es) 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN103877564A (zh) * 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
CA2714120A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
AU2009246053B2 (en) 2008-05-14 2014-07-24 Agriculture Victoria Services Pty Ltd. Use of angiogenin or angiogenin agonists for treating diseases and disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102245773B (zh) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
EP3345921A1 (en) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Use of anti-actriib antibodies for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CA2773494A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
EP3818988A1 (en) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
US20140322758A1 (en) 2011-10-21 2014-10-30 Pfizer Inc. Addition of iron to improve cell culture
EP2802351B1 (en) 2012-01-09 2019-03-27 ADC Therapeutics SA Agents for treating triple negative breast cancer
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014000042A1 (en) * 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
DK2880053T3 (da) 2012-08-01 2020-05-11 Ikaika Therapeutics Llc Lindring af vævsskade og fibrose via anti-LTBP4-antistof
CN104822826B (zh) 2012-10-15 2019-04-30 百时美施贵宝公司 用于蛋白产生的哺乳动物细胞培养过程
JP6401172B2 (ja) 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
EP3308796B1 (en) 2012-11-02 2021-07-14 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
CN104725513A (zh) * 2013-12-20 2015-06-24 中国科学院上海生命科学研究院 融合蛋白及其在治疗多发性硬化中的用途
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
MD4801C1 (ro) 2014-12-03 2022-10-31 Celgene Corporation Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
IL285371B (en) * 2016-01-06 2022-07-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
NZ745635A (en) 2016-03-31 2024-03-22 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
JP2022514778A (ja) 2018-12-21 2022-02-15 ノースウェスタン ユニバーシティ 筋膜損傷の予防および治療におけるアネキシンの使用
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
IE930961L (en) 1984-07-06 1986-01-06 Sandoz Ag Lymphokine production and purification
DE3588058T3 (de) 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4798885A (en) * 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) * 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
ZA874681B (en) * 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
WO1990011366A1 (en) 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
US5106748A (en) * 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5041538A (en) * 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
AU645244B2 (en) 1988-04-08 1994-01-13 Genetics Institute, Llc Bone and cartilage inductive compositions
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5166190A (en) 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
JPH06500991A (ja) 1990-05-16 1994-01-27 ジェネティックス・インスティテュート・インコーポレイテッド 骨および軟骨誘導蛋白質
WO1992005199A1 (en) 1990-09-26 1992-04-02 Genetics Institute, Inc. Bmp-5 derivatives
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
ATE242639T1 (de) 1992-07-31 2003-06-15 Curis Inc Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6673534B1 (en) * 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
CA2161808C (en) 1993-05-12 2008-08-05 Anthony J. Celeste Bmp-11 compositions
AU677866B2 (en) 1993-08-26 1997-05-08 Board Of Trustees Of The University Of Illinois, The Neural regeneration using human bone morphogenetic proteins
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
DE69534468T2 (de) * 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5466190A (en) * 1994-07-25 1995-11-14 Deere & Company Precleaner for a cleaning shoe
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
JPH10262688A (ja) * 1994-11-30 1998-10-06 Univ Rockefeller 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR20000064752A (ko) 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
AR008077A1 (es) * 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
JP4368522B2 (ja) * 1997-07-14 2009-11-18 ユニバーシティー オブ リージ 哺乳動物におけるダブルマスル化を引き起こすミオスタチン遺伝子の変異
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
GB2345397B (en) * 1997-08-19 2001-10-31 Citizen Watch Co Ltd Piezoelectric vibrator
EP1015468A4 (en) 1997-08-29 2000-09-06 Human Genome Sciences Inc FOLLISTATINE-3
WO1999024057A2 (en) * 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
WO1999056768A1 (en) 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000011163A1 (en) 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
NZ513642A (en) * 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
AU782493B2 (en) * 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
TR200400621T2 (tr) 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL350983A1 (en) * 2001-11-30 2003-06-02 Advanced Digital Broadcast Ltd Method of scanning a high-frequency signal band and apparatus therefor
MXPA04008149A (es) * 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
MX2007011400A (es) 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
US20060240488A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents

Also Published As

Publication number Publication date
US20120252884A1 (en) 2012-10-04
NO333427B1 (no) 2013-06-03
US7560441B2 (en) 2009-07-14
CL2009000648A1 (es) 2009-06-12
MXPA03007063A (es) 2004-10-15
TWI329129B (en) 2010-08-21
WO2002068650A3 (en) 2003-08-21
US20100305194A1 (en) 2010-12-02
CA2437218A1 (en) 2002-09-06
ES2284828T3 (es) 2007-11-16
HK1062457A1 (en) 2004-11-05
AR032567A1 (es) 2003-11-12
WO2002068650A2 (en) 2002-09-06
US20070238683A1 (en) 2007-10-11
JP4280071B2 (ja) 2009-06-17
NZ550297A (en) 2008-04-30
JP5013618B2 (ja) 2012-08-29
US7202210B2 (en) 2007-04-10
US8222384B2 (en) 2012-07-17
PL207202B1 (pl) 2010-11-30
PL212078B1 (pl) 2012-08-31
SG187989A1 (en) 2013-03-28
ATE357519T1 (de) 2007-04-15
JP2005507637A (ja) 2005-03-24
US8710025B2 (en) 2014-04-29
JP2009091366A (ja) 2009-04-30
CA2674673A1 (en) 2002-09-06
WO2002068650B1 (en) 2004-01-08
EP1397492A2 (en) 2004-03-17
NO20033456L (no) 2003-10-06
US7737116B2 (en) 2010-06-15
US20030104406A1 (en) 2003-06-05
SG165982A1 (en) 2010-11-29
JP2006001938A (ja) 2006-01-05
DK1397492T3 (da) 2007-07-09
PL372888A1 (en) 2005-08-08
BR0207110A (pt) 2005-08-16
DE60219006T2 (de) 2007-12-13
ZA200306064B (en) 2006-02-22
EP1397492B1 (en) 2007-03-21
TW200526779A (en) 2005-08-16
PT1397492E (pt) 2007-06-15
US20070149455A1 (en) 2007-06-28
AU2002243852B2 (en) 2007-08-16
DE60219006D1 (de) 2007-05-03
US20140228289A1 (en) 2014-08-14
CY1106629T1 (el) 2012-01-25
NZ527286A (en) 2006-11-30
ZA200508954B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
NO20033456L (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
DE60326611D1 (de) N und dergleichen
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
DK1429769T3 (da) Nye formuleringer og anvendelse deraf
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
DK1429770T3 (da) Nye formuleringer og anvendelse deraf
DE60205008D1 (de) Kettelverfahren und -vorrichtung
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
DE60219418D1 (de) Silanylphenole und -naphthole
ATE354561T1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen
DE50110467D1 (de) Staffelei
DE60235139D1 (de) Recheneinheit und Empfangseinheit
ITMI20011210A0 (it) Corticosteroidi-21-glicolati e 21-acilglicolati
SE0104404D0 (sv) New methods and use
NO20042856L (no) Substituerte 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner og anvendelse av samme
ATE332659T1 (de) Staffelei

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees